Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung

@article{Grob2012HeterogeneityOE,
  title={Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung},
  author={Tobias J. Grob and Ivonne Kannengiesser and Maria Ch Tsourlakis and Djordje Atanackovic and Alexandra K{\"o}nig and Yogesh Kumar Vashist and Hans Klose and Andreas H Marx and Susan Koops and Ronald Simon and Jakob Robert Izbicki and C Carsten Bokemeyer and Guido Sauter and Waldemar Wilczak},
  journal={Modern Pathology},
  year={2012},
  volume={25},
  pages={1566-1573}
}
The HER2 protein, encoded by the ERBB2 gene, is a molecular target for the treatment of breast and gastric cancer by monoclonal antibodies or tyrosine kinase inhibitors. While intratumoral heterogeneity of ERBB2 amplification is rare in breast cancer it is reported to be frequent in bladder and colorectal cancer. To address the potential heterogeneity of the HER2 status in adenocarcinomas, squamous cell carcinomas and large cell undifferentiated carcinomas of the lung, 590 tumors were analyzed… CONTINUE READING